ClinicalTrials.Veeva

Menu

Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer

A

Asan Medical Center

Status and phase

Completed
Phase 2

Conditions

Pleural Effusion, Malignant
Non-small Cell Carcinoma

Treatments

Drug: intrapleural docetaxel administration

Study type

Interventional

Funder types

Other

Identifiers

NCT03394105
C2015-00353_Pleurodesis

Details and patient eligibility

About

In this trial, the effect of intrapleural docetaxel administration using medical pleuroscopywill be evaluated in Lung Cancer patient with malignant effusion.

Full description

This study is designed to be pilot, single-center, open-label, single-arm, prospective, phase II trial of patient with NSCLC with pleurla effusion. Approximately 40 patients will be enrolled into the trial, and study will be performed to 31Dec2018 from IRB and Korea: MFDS approval date.

Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer. Response evaluation will be done until confiramtion of disease progression.

Enrollment

4 patients

Sex

All

Ages

20 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 20, and NSCLC patients with malignant pleural effusion and related symptoms
  • ECOG ≤ 2
  • Blood test ANC≥ 1500/mm3, Hb ≥ 8.0g/dl, platelet count ≥ 100000/mm3 Serum creatinine ≤ 1.8mg/dl, Total bilirubin within normal limits, Transaminases ≤ 1.5 x UNL, Alkaline phosphatase ≤ 2.5 X UNL BUN ≤ 25mg/dl, Creatinine clearance ≥ 50ml/min
  • Negative serum or urine pregnancy test for women for childbearing age
  • Patients who provide written informed consent for the study

Exclusion criteria

  • Age < 20
  • Patients who were previously perfomed pleurodesis
  • Patients who were previously treated with thoracic radiosurgery
  • Patinet with bilateral pleural effusion
  • Age ≥ 80yrs
  • Patients with histories of hypersensitivity to Docetaxel
  • Patients with cardiovascular, respiratory, hepatic, renal, gastrointestinal, neunological disease, asthma, MI, stroke, arrhythmia, uncontrolled hypertionsion, etc. that would effect absorption, distribution, and metabolism of IP or be risk factors during IP administrion.
  • Patients who could not understand the study procedure

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

4 participants in 1 patient group

intrapleural docetaxel administration
Experimental group
Description:
Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer.
Treatment:
Drug: intrapleural docetaxel administration

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems